【摘要】 目的探讨肌注利培酮微球与口服利培酮治疗精神分裂症的疗效,为临床选择药物提供依据。方法将80例精神分裂症患者随机分成肌注利培酮微球(RLAI)组及口服利培酮片组,治疗12周。在治疗第1、4、8、12周用阳性与阴性症状量表(PANSS)、临床疗效总评量表(CGI-SI)、不良反应量表(TESS)评定疗效和不良反应。结果两组PANSS总分及CGI-SI评分均比治疗前显著下降(P<0.01),与基线比较,PANSS评分自4周末以后均出现显著差异,两组疗效相当。RLAI组的不良反应明显低于口服利培酮片组(P<0.05)。结论肌注利培酮微球与口服利培酮片治疗精神分裂症的疗效相当,RLAI组的不良反应较口服利培酮少而轻。肌注利培酮微球治疗精神分裂症安全有效,患者对治疗依从性比口服利培酮更好。更多还原

【Abstract】 Objective To investigate the efficacy of intramuscular risperidone microspheres and oral risperidone in the treatment of schizophrenia,and to provide the basis for clinical drug of choice.Methods 80 cases of patients with schizophrenia were randomly divided into intramuscular risperidone microspheres(RLAI) group and the oral risperidone piece group,12 weeks of treatment.Evaluate the efficacy and adverse reactions in the treatment of 1,4,8 and 12 weeks using the Positive and Negative Syndrome Scale(PANSS),the Clinical Global Impression(CGISI),adverse reactions Scale(TESS).Results The PANSS total score and CGI-SI score in both groups was significantly decreased(P <0.01) than before treatment.Compared with baseline,there are significant differences in the PANSS score after 4 weeks.Treatment efficiency in two group is very close to.The adverse drug reactions of RLAI group was significantly lower than the oral risperidone group(P <0.05).Conclusion The efficacy of intramuscular risperidone microspheres and oral risperidone tablets in the treatment of schizophrenia is very close to,The RLAI group adverse reactions are less and lighter than oral risperidone.Intramuscular risperidone microspheres for treatment of schizophrenia is safe and effective,and Patient treatment compliance is better than oral risperidone.更多还原